Dr. Addepalli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
40 Duke Medicine Cir
Durham, NC 27710Phone+1 919-684-8111
Education & Training
Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2014 - 2017
University of Pennsylvania Health SystemResidency, Internal Medicine, 2011 - 2014
Gandhi Medical CollegeClass of 2002
Certifications & Licensure
NC State Medical License 2014 - 2025
PA State Medical License 2011 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 222 citationsTocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.Chipman Rg Stroud, Aparna Madhukeshwar Hegde, Cynthia R. Cherry, Abdul Rafeh Naqash, Nitika Sharma
Journal of Oncology Pharmacy Practice. 2019-04-01
Press Mentions
Nivolumab May Be Ineffective in Lung Cancer Pts with Hepatic MetastasesMarch 9th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
